donepezil has been researched along with Fra(X) Syndrome in 5 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study was designed as a 12-week, randomized, double-blind, placebo-controlled pilot study to evaluate the effectiveness and safety of donepezil in boys with fragile X syndrome." | 9.17 | Effectiveness and safety of donepezil in boys with fragile x syndrome: a double-blind, randomized, controlled pilot study. ( Arya, R; Chauhan, S; Chowdhury, MR; Dwivedi, SN; Gulati, S; Gupta, N; Gupta, YK; Kabra, M; Kalra, V; Sahu, JK; Sapra, S, 2013) |
| "The present study was designed as a 12-week, randomized, double-blind, placebo-controlled pilot study to evaluate the effectiveness and safety of donepezil in boys with fragile X syndrome." | 5.17 | Effectiveness and safety of donepezil in boys with fragile x syndrome: a double-blind, randomized, controlled pilot study. ( Arya, R; Chauhan, S; Chowdhury, MR; Dwivedi, SN; Gulati, S; Gupta, N; Gupta, YK; Kabra, M; Kalra, V; Sahu, JK; Sapra, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruno, JL | 1 |
| Hosseini, SH | 1 |
| Lightbody, AA | 2 |
| Manchanda, MK | 1 |
| Reiss, AL | 2 |
| Kesler, SR | 1 |
| Hagerman, R | 2 |
| Lauterborn, J | 1 |
| Au, J | 1 |
| Berry-Kravis, E | 1 |
| Sahu, JK | 1 |
| Gulati, S | 1 |
| Sapra, S | 1 |
| Arya, R | 1 |
| Chauhan, S | 1 |
| Chowdhury, MR | 1 |
| Gupta, N | 1 |
| Kabra, M | 1 |
| Gupta, YK | 1 |
| Dwivedi, SN | 1 |
| Kalra, V | 1 |
| Bourgeois, JA | 1 |
| Farzin, F | 1 |
| Brunberg, JA | 1 |
| Tassone, F | 1 |
| Hagerman, P | 1 |
| Zhang, L | 1 |
| Hessl, D | 1 |
1 review available for donepezil and Fra(X) Syndrome
| Article | Year |
|---|---|
Fragile X syndrome and targeted treatment trials.
Topics: Animals; Anti-Bacterial Agents; Antioxidants; Baclofen; Brain-Derived Neurotrophic Factor; Central N | 2012 |
3 trials available for donepezil and Fra(X) Syndrome
| Article | Year |
|---|---|
Brain circuitry, behavior, and cognition: A randomized placebo-controlled trial of donepezil in fragile X syndrome.
Topics: Adolescent; Adult; Brain; Child; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Donepezi | 2019 |
Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study.
Topics: Adolescent; Adult; Case-Control Studies; Choline; Cholinesterase Inhibitors; Cognition; Creatine; Do | 2009 |
Effectiveness and safety of donepezil in boys with fragile x syndrome: a double-blind, randomized, controlled pilot study.
Topics: Adolescent; Child; Child Behavior Disorders; Child Development Disorders, Pervasive; Donepezil; Dose | 2013 |
1 other study available for donepezil and Fra(X) Syndrome
| Article | Year |
|---|---|
Dementia with mood symptoms in a fragile X premutation carrier with the fragile X-associated tremor/ataxia syndrome: clinical intervention with donepezil and venlafaxine.
Topics: Aged; Antidepressive Agents, Second-Generation; Ataxia; Atrophy; Brain; Cyclohexanols; Dementia; Dom | 2006 |